InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
2
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Breitmeyer James B, Director. Insider active across 3 companies, notably Vaxart, Inc.. Aggregated, 10 filings have been published. Split: 2 buys · 0 sell. Total volume traded: €64k. History available since 3 January 2022. The latest transaction was filed on 16 July 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Breitmeyer James B
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报10 总计
8,315 股0Common StockSEC:0001437749-26-023810:0
78,800 股0Common StockSEC:0001437749-26-014528:0
50,955 股@ US$0.496113.9% 占其流量Common StockSEC:0001209191-24-000970:0
47,992 股@ US$0.369.5% 占其流量Common StockSEC:0001209191-23-041319:0
100,000 股@ US$0.2915.7% 占其流量Common StockSEC:0001209191-23-024390:0
标准退出：2023年7月12日 (T+90)
27,793 股@ US$1.0215.9% 占其流量Common StockSEC:0001209191-23-002033:0
185,625 股0Common StockSEC:0001209191-22-043735:0
1,250 股Common StockSEC:0000899243-22-010312:0
25,000 股@ US$1.683250.0% 占其流量Common StockSEC:0001209191-22-005556:0
标准退出：2022年4月27日 (T+90)
128,557 股0Common StockSEC:0001209191-22-001974:0
10 条申报中的 10 条
About Breitmeyer James B
James B. Breitmeyer is the Chief Executive Officer of Vaxart, Inc., Oncternal Therapeutics, Inc., and ZOGENIX, INC. He leads these companies with a focus on innovation and the development of new treatments. His leadership is essential for the growth of these firms.
